PROCEPT BioRobotics announced positive three-month results from the WATER III trial, comparing its Aquablation therapy to laser enucleation for treating large prostates (80-180mL). The study found Aquablation therapy provided similar symptom relief with significantly lower rates of ejaculatory dysfunction (14.8% vs. 77.1%) and stress incontinence (0% vs. 9.1%) compared to laser enucleation. Furthermore, the Aquablation group experienced no procedural transfusions.
This data is crucial for urologists and patients as it suggests a potential paradigm shift in BPH treatment for larger prostates. Current surgical options often involve a trade-off between symptom relief and preservation of sexual function and continence. Aquablation therapy’s demonstrated ability to minimize these complications offers a more desirable outcome for patients, potentially increasing their willingness to seek treatment and improving overall quality of life. This could translate to increased adoption of the procedure by urologists and higher market share for PROCEPT BioRobotics.
The WATER III trial included 186 men and will continue to follow patients for five years. The absence of procedural transfusions in the Aquablation group highlights the therapy’s safety and reproducibility in managing bleeding risk. These findings build upon existing clinical data from previous WATER studies, further solidifying Aquablation’s potential as a standard of care for BPH across various prostate sizes.
This positive data strengthens Aquablation’s position in the growing BPH treatment market. The improved patient outcomes, particularly regarding sexual function and continence, could drive greater adoption of the procedure, making Aquablation a preferred choice for both patients and urologists. This, in turn, positions PROCEPT BioRobotics for continued growth and market leadership in the surgical robotics space for urology.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
